about
Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisHow the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis VaccinesIs a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.Identification and therapeutic potential of a vitronectin binding region of meningococcal msfAntibody repertoire profiling with mimotope arrays.Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes.Glycoconjugate vaccines: an update.Novel approaches to Neisseria meningitidis vaccine design.The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.Abundance and co-occurrence of extracellular capsules increase environmental breadth: Implications for the emergence of pathogens.Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.Chromatographic analysis of the Escherichia coli polysialic acid capsule.Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.Challenges and opportunities for Meningococcal vaccination in the developing world.Meningococcal Vaccines: Current Status and Emerging Strategies.Determination of the binding affinities of Neisseria meningitidis serogroup W capsule polymerase with two nucleotide sugar substratesMeningitis B vaccination: knowledge and attitudes of pediatricians and parents in Greece
P2860
Q26779489-CB6628BB-237B-4868-9D4C-97B54679BF63Q26782340-E2D4C578-F89E-4651-924B-5BB93263B7E1Q34153704-E0602FBE-5836-4A74-A8C3-036164BBCB48Q34785389-C061BE85-EAF4-4230-861F-6A625DC613E5Q35235006-7A0E04EA-9855-4FE1-88E5-C3FD93716216Q36215753-1BB5A296-F91E-4128-BDC1-DD3418362C78Q37340824-3868F791-5D27-47B9-8DBD-43828EBD3B6DQ37367077-934628D7-2096-446F-B960-7D55ACEA3804Q37514748-DD29EEC3-4D8F-457C-975C-F7E46B899D8DQ38035276-CBD2CF65-B5F0-4282-AA0E-3A5F60A754B1Q38286346-9D63EDDE-0C4C-4C4B-BFB9-77FA566C7170Q39215403-7A3E79C4-F11A-430F-93A6-A34E6C95F623Q39816694-F44A4513-D2D5-4D19-9FDE-A45F87DE02D3Q39852648-8E9C760D-32E4-4EBA-BA6B-74A4581855ABQ40120673-F988A994-1490-4481-92AB-A956D878BDAEQ41666578-866229C0-98DE-403C-81BD-82380A195E04Q41866766-74EB8967-BFB1-4DD6-9F4F-B1F7B784CA86Q47707104-2DD33C41-9C87-4552-8017-76675DB56D1CQ49377063-68A54B7C-16D5-4B4C-8853-1B257B9C872BQ52679153-A63A4B44-3CEC-421E-A859-5718AFBCD648Q57175765-2C3A3EBE-003E-4766-BB15-C632AD695DCFQ58692203-291D59E4-4568-416E-9FC6-74C27D4711F3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Meningococcal glycoconjugate vaccines.
@ast
Meningococcal glycoconjugate vaccines.
@en
type
label
Meningococcal glycoconjugate vaccines.
@ast
Meningococcal glycoconjugate vaccines.
@en
prefLabel
Meningococcal glycoconjugate vaccines.
@ast
Meningococcal glycoconjugate vaccines.
@en
P2860
P356
P1433
P1476
Meningococcal glycoconjugate vaccines
@en
P2093
Donatella Panatto
Roberto Gasparini
P2860
P304
P356
10.4161/HV.7.2.13717
P577
2011-02-01T00:00:00Z